NCT00002754View on ClinicalTrials.gov

Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 28, 1993

Primary Completion Date

April 30, 2001

Study Completion Date

April 30, 2001

Conditions
Brain and Central Nervous System TumorsMelanoma (Skin)Metastatic Cancer
Interventions
BIOLOGICAL

monoclonal antibody Me1-14 F(ab')2

Trial Locations (1)

27710

Duke Comprehensive Cancer Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Duke University

OTHER

NCT00002754 - Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors | Biotech Hunter | Biotech Hunter